speaker-icon

Latest Posts

Partex-Group-presents-results-from-a-pilot-project-with-AIO

18

Mar 24

Innovative AI technology in oncology: Partex Group presents results from a pilot project

During the German Cancer Congress 2024 in Berlin, the companies Innoplexus AG /Amrit AG, companies of Partex N.V., presented the...
Read More
Partex-Sanofi-press-release-illustration

14

Mar 24

Partex NV Forges Collaboration with Sanofi in AI-Based Dossier Enrichment for Out-Licensing

Frankfurt, Germany; 14 March 2024 Partex Group, a pioneer in AI-driven drug discovery, today announces a collaboration with global pharmaceutical...
Read More

Innoplexus wins Horizon Interactive Gold Award for Curia App

Read More

WHITEPAPERS

EY-report-banner

Autoimmune
Index report

Autoimmune Index report provides you with a perspective on the new commercial and clinical opportunities by assessing their clinical innovation aspect. Innoplexus’ AI based CTP engine was leveraged to predict the success probability of clinical assets.
CTP-model-banner

Innoplexus’
CTP model

Innoplexus’ CTP model forecasts the outcome of clinical studies and may serve as an early indicator for future stock movements.
Gene-therapy-banner

Gene
Therapy

Gene therapy promises to hold the cure to a number of diseases which, until now, have been considered incurable. By replacing a faulty gene in a patient’s DNA or repairing a defective gene by gene editing, gene therapy can provide a one-time treatment option for diseases such as genetic blindness, muscular dystrophy, blood cancer. Read our recent whitepaper: Advancements in gene therapy – usage of AAV vectors here.
antigen-banner

Emergence of
chimeric antigen

Emergence of chimeric antigen receptor-t (CAR-T) cell therapies for cancer treatment